Northern Oak Wealth Management Inc. Has $647,000 Holdings in Eli Lilly And Co (LLY)

Northern Oak Wealth Management Inc. decreased its holdings in shares of Eli Lilly And Co (NYSE:LLY) by 5.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,589 shares of the company’s stock after selling 310 shares during the quarter. Northern Oak Wealth Management Inc.’s holdings in Eli Lilly And Co were worth $647,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also modified their holdings of LLY. GYL Financial Synergies LLC purchased a new stake in Eli Lilly And Co during the fourth quarter valued at about $225,000. 1832 Asset Management L.P. boosted its holdings in shares of Eli Lilly And Co by 965.3% during the fourth quarter. 1832 Asset Management L.P. now owns 1,711,846 shares of the company’s stock worth $198,074,000 after purchasing an additional 1,551,150 shares during the period. AT Bancorp boosted its holdings in shares of Eli Lilly And Co by 12.4% during the fourth quarter. AT Bancorp now owns 3,984 shares of the company’s stock worth $461,000 after purchasing an additional 440 shares during the period. Family Legacy Inc. boosted its holdings in shares of Eli Lilly And Co by 7.1% during the fourth quarter. Family Legacy Inc. now owns 6,542 shares of the company’s stock worth $757,000 after purchasing an additional 435 shares during the period. Finally, Principal Financial Group Inc. boosted its holdings in shares of Eli Lilly And Co by 17.3% during the fourth quarter. Principal Financial Group Inc. now owns 1,734,994 shares of the company’s stock worth $200,773,000 after purchasing an additional 255,461 shares during the period. 79.59% of the stock is currently owned by institutional investors and hedge funds.

In related news, insider Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $127.01, for a total transaction of $127,010.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Lilly Endowment Inc sold 51,766 shares of the firm’s stock in a transaction that occurred on Tuesday, January 15th. The stock was sold at an average price of $117.74, for a total transaction of $6,094,928.84. Following the completion of the sale, the insider now owns 117,963,538 shares in the company, valued at approximately $13,889,026,964.12. The disclosure for this sale can be found here. Insiders sold 834,190 shares of company stock valued at $102,516,602 over the last 90 days. 0.11% of the stock is currently owned by company insiders.

Shares of LLY opened at $128.30 on Monday. The company has a quick ratio of 1.38, a current ratio of 1.73 and a debt-to-equity ratio of 1.07. Eli Lilly And Co has a one year low of $74.51 and a one year high of $130.75. The stock has a market capitalization of $132.84 billion, a price-to-earnings ratio of 23.12, a P/E/G ratio of 2.57 and a beta of 0.33.

Eli Lilly And Co (NYSE:LLY) last issued its quarterly earnings data on Wednesday, February 6th. The company reported $1.33 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.36 by ($0.03). Eli Lilly And Co had a return on equity of 44.66% and a net margin of 13.16%. The company had revenue of $6.44 billion during the quarter, compared to analysts’ expectations of $6.28 billion. During the same quarter last year, the business earned $1.14 earnings per share. The business’s quarterly revenue was up 4.5% on a year-over-year basis. Sell-side analysts predict that Eli Lilly And Co will post 5.66 EPS for the current fiscal year.

A number of research firms have recently weighed in on LLY. Zacks Investment Research upgraded shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $121.00 target price for the company in a report on Wednesday, December 19th. Credit Suisse Group set a $121.00 target price on shares of Eli Lilly And Co and gave the stock a “hold” rating in a report on Friday. UBS Group began coverage on shares of Eli Lilly And Co in a report on Wednesday, March 20th. They set a “buy” rating and a $74.51 target price for the company. Bank of America set a $129.00 target price on shares of Eli Lilly And Co and gave the stock a “hold” rating in a report on Thursday. Finally, Citigroup lowered shares of Eli Lilly And Co from a “buy” rating to a “neutral” rating and set a $115.00 price objective for the company. in a report on Monday, November 26th. Ten equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $115.68.

ILLEGAL ACTIVITY WARNING: This article was first published by Markets Daily and is the sole property of of Markets Daily. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.themarketsdaily.com/2019/03/25/northern-oak-wealth-management-inc-has-647000-holdings-in-eli-lilly-and-co-lly.html.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Read More: What are different types of coverage ratios?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.